Current concepts in age related macular degeneration

1 October 2008
Volume 09, Issue 4

A review of the modern classifications of AMD and available treatments.


Age-related macular degeneration (ARMD) is the commonest cause of visual impairment leading to blind registration among older adults in the western world. Following recently published trials, ophthalmologists around the world now have the knowledge and the drugs to improve visual outcomes and to provide much-needed hope to patients with wet macular degeneration. Further, many research trials are currently under way with more funding to find an even more suitable and effective treatment modality for macular degeneration.

Sign in to continue

Forgotten password?

Sign in to view the article

Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

A glance at what’s happening in the world of technology - Spring 2023.

As age-related macular degeneration progresses, part of the visual cortex starts to atrophy. But which way does the causal relationship work, asks Kim Thomas, and what does it mean for treatments focused on the retina if the brain has entered an irreversible decline?

The effort, cost and logistics of managing treatment for eye conditions can have a big impact on patients’ quality of life. What can be done to minimise their treatment burden?